Mineralocorticoid Receptor Inhibitors
2 drugsAbout Mineralocorticoid Receptor
The Mineralocorticoid Receptor (MR) is a ligand-activated transcription factor that regulates sodium and potassium balance, blood volume, and blood pressure. Primarily known for kidney function, it is also expressed in the heart and brain, influencing various physiological processes.
The broad expression profile of MR makes it a compelling drug target, particularly in the cardiovascular therapeutic area. Currently, there is no genetic evidence available linking the Mineralocorticoid Receptor to specific diseases.
Two FDA-approved drugs target MR: Eplerenone and Kerendia. Both are small molecules, with Novartis and Bayer marketing these drugs across cardiovascular and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Proteinuria with only 2 trials.
- phase2 represents biological uncertainty with 56% completion.
Top Mineralocorticoid Receptor Drugs
Novartis and Bayer are the only companies with approved drugs targeting the Mineralocorticoid Receptor.
Limited competition suggests a high barrier to entry, but also an opportunity for new players with differentiated therapies.
Mineralocorticoid Receptor Drug Modality Landscape
Modalities
Routes of Administration
Mineralocorticoid Receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide differentiation in a small molecule-heavy field.
Mineralocorticoid Receptor Clinical Trials 115 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 13 | 2 | 0 | 87% |
| Phase 2 | 27 | 13 | 8 | 6 | 62% |
| Phase 3 | 30 | 12 | 1 | 16 | 92% |
| Phase 4 | 43 | 13 | 8 | 19 | 62% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Mineralocorticoid Receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Mineralocorticoid Receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Mineralocorticoid Receptor Drug Approval Timeline (2008 - 2021)
The first drug was approved in 2008 (Eplerenone), with the most recent approval in 2021 (Kerendia), spanning 14 years.
Relatively slow approval rate indicates potential challenges in drug development or a saturated market for existing approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 82 clinical trials targeting Mineralocorticoid Receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities